Mr. Bratton has served on the board of directors since 2004. He manages the investment operations of the Edward P. Bass Group of Fort Worth, Texas, or the Bass Group. Since 1983, he has served as an investment professional with various organizations utilizing alternative asset strategies. Since 1997, Mr. Bratton has been President of Bratton Capital Management L.P., a firm that provides investment management services to the Bass Group.
Dr. Brown joined the board in March 2007. He is a Founding Managing Director and member of the Investment Committee at HealthCare Royalty Partners. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced surgery in a community setting where he also founded and led an HMO. He brings particular expertise on the technical, clinical and medical evaluation of products as well as the payor / reimbursement analysis. He has been involved in sourcing, diligencing and closing more than $1 billion of royalty financings. In addition, he leads the firm's European business development efforts and manages various operational functions of the firm. Previously, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm's royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale, an MD from SUNY Upstate Medical Center and an MBA from Harvard. He currently serves on the boards of Invuity and MonoSol Rx.
Mr. Cochran has served on the board of directors since 2004. He has been a partner of Bratton Capital Management L.P. since October 1998, and is responsible for its private equity investments. Mr. Cochran is also responsible for the operations of Crestline Management, a credit-oriented alternative asset management platform. Prior to joining Bratton Capital Management L.P., he spent 10 years with KPMG focused primarily on audit and merger and acquisition due diligence.
Mr. Costa joined the board in 2015. His professional experience includes over 30 years in executive and senior operating management positions within the pharmaceutical, health care, and life sciences industries. Currently, Mr. Costa sits on the board of Cytokinetics Inc. and is chairman of Metabon Inc. He has also served as a board member to numerous other public and private companies and charitable organizations. Mr. Costa is Of Counsel at the law firm Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan in Raleigh, N.C. In addition to his legal practice, Mr. Costa's experience includes President, Chief Operating Officer, and Vice Chairman of Quintiles Transnational Corp. where during his tenure he had responsibility for all operating divisions and worldwide business development.. He is also a nationally recognized speaker on leadership, as well as legal and policy issues affecting the pharmaceutical industry. Mr. Costa earned a B.S. in pharmacy and his J.D. from St. John's University.
Mr. Tanki joined the board in January 2007. He is a certified public accountant and retired in 1998 as a Senior Partner of Coopers & Lybrand, the predecessor of PricewaterhouseCoopers. Mr. Tanki was a member of the Coopers & Lybrand Executive Management Committee from 1994 to 1995 and the Firm Council from 1982 to 1994. He served as the Director of Accounting and SEC Technical Services as well as the Business Assurance Partner In Charge of the New York Practice. He served on the Auditing Standards Board of the American Institute of Certified Public Accountants. Mr. Tanki has been a member of the board of directors of Computer Horizons Inc. since November 2005.